Table 3.
Magnetic resonance imaging manifestations in recurrent tumors
| Participant | Location | Size (mm) | AFP levels | Enhancement patterns | T2WI | DWI | Hepatobiliary phase |
|---|---|---|---|---|---|---|---|
| 1 | |||||||
| Pre-SBRT | S2 | 19 | 858.4 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity |
| 1 month | 13 | 68.27 | APHE and wash-out | Iso-hyperintensity | Iso-hyperintensity | – | |
| 3 months | 11 | 314.4 | non-enhancement | Iso-hyperintensity | Iso-hyperintensity | – | |
| 6 months | 11 | 448.1 | non-enhancement | Iso-hyperintensity | Iso-hyperintensity | hypoinTensity | |
| 9 months * | 20 | 656.2 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity | |
| 12 months | 23 | 2479 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity | |
| 2 | |||||||
| Pre-SBRT | S1 | 18 | 6.27 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity |
| 1 month | 16 | 12.23 | APHE and wash-out | iso-Hyperintensity | Isointensity | – | |
| 3 months | 9 | 19.61 | APHE and wash-out | Isointensity | Isointensity | – | |
| 6 months * | 20 | 55.58 | APHE and wash-out | Iso-hyperintensity | Iso-hyperintensity | – | |
| 9 months | 25 | 101.5 | APHE and wash-out | Iso-hyperintensity | Iso-hyperintensity | – | |
| 12 months | 28 | 421.2 | APHE and wash-out | Hyperintensity | Hyperintensity | – | |
| 3 | |||||||
| Pre-SBRT | S8 | 24 | 4.01 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity |
| 1 month | 20 | 6.43 | APHE and wash-out | Iso-hyperintensity | Iso-hyperintensity | – | |
| 3 months | 17 | 5.92 | APHE and wash-out | Iso-hyperintensity | Isointensity | – | |
| 6 months | 15 | 6.42 | delayed enhancement | Isointensity | isointensity | – | |
| 9 months | 14 | 5.49 | delayed enhancement | Isointensity | Isointensity | – | |
| 18 months | 13 | 4.42 | delayed enhancement | Isointensity | Isointensity | – | |
| 20 months* | 22 | 4.04 | APHE and wash-out | Isointensity | Isointensity | – | |
| 28 months | 27 | 4 | APHE and wash-out | Iso-hyperintensity | Hyperintensity | Hypointensity | |
| 4 | |||||||
| Pre-SBRT | S7 | 14 | 1.14 | APHE and wash-out | Hyperintensity | Hyperintensity | – |
| 1 month | 13 | 1.97 | non-enhancement | Iso-hyperintensity | hyperintensity | – | |
| 3 months | 12 | 1.86 | non-enhancement | Iso-hyperintensity | Hyperintensity | Hypointensity | |
| 6 months* | 17 | 2.43 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity | |
| 5 | |||||||
| Pre-SBRT | S8 | 35 | 9.54 | APHE and wash-out | Hyperintensity | Hyperintensity | – |
| 1 month | 30 | 13.27 | APHE and wash-out | Hyperintensity | Iso-hyperintensity | – | |
| 3 months | 17 | 9.49 | APHE and wash-out | Iso-hyperintensity | Iso-hyperintensity | – | |
| 6 months* | 22 | 6.82 | APHE and wash-out | Hyperintensity | Hyperintensity | – | |
| 9 months | 40 | 5.32 | APHE and wash-out | Hyperintensity | Hyperintensity | – | |
| 6 | |||||||
| Pre-SBRT | S2 | 26 | 6.95 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity |
| 1 month | 22 | 8.02 | APHE and wash-out | Hyperintensity | Iso-hyperintensity | – | |
| 3 months | 17 | 5.93 | APHE and wash-out | Iso-hyperintensity | Iso-hyperintensity | – | |
| 6 months* | 22 | 3.64 | APHE and wash-out | Iso-hyperintensity | Hyperintensity | Hypointensity | |
| 9 months | 24 | 3.3 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity | |
| 12 months | 26 | 2.39 | APHE and wash-out | Hyperintensity | Hyperintensity | Hypointensity |
*The bold parts of the table are indicative of the tumor progression time in the corresponding patient
SBRT Stereotactic body radiation therapy, APHE Arterial phase hyperenhancement, AFP alpha-fetoprotein, T1WI T1-weighted imaging, T2WI T2-weighted imaging, DWI diffusion-weighted imaging